Empagliflozin safe in acute HF, improves 'Clinical Benefit' over time

Published On 2021-12-02T10:42:45+05:30 | Updated On 2 Dec 2021 5:12 AM GMT

Overview

Patients with acute heart failure were safely started on empagliflozin a median of 3 days after hospitalization and were 36% more likely to "experience a clinical benefit" over the next 90 days compared with patients taking a placebo, the EMPULSE trial highlights.

The benefits of empagliflozin in this very early acute setting, included better survival, fewer hospitalizations, and greater improvements quality of life (QoL)—all of which made up the primary composite endpoint in this study

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 3 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped.

Dr. Prem Aggarwal

Dr Prem Aggarwal, (DNB Cardiology) is an Cardiologist by profession and also the Co-founder of Medical Dialogues. An avid researcher, he is currently associated with GB Pant Hospital (GIPMER) New Delhi as a PhD Fellow pursuing his research on the topic of Angioplasties on Surgical Rejects